Modulation of plasmacytoid dendritic cell function in multiple sclerosis

Trial Profile

Modulation of plasmacytoid dendritic cell function in multiple sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 12 Sep 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 25 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jun 2008 Bayer reported as trial sponsor by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top